Silibinin Inhibit Cell Migration through Downregulation of RAC1 Gene
                    Expression in Highly Metastatic Breast Cancer Cell Line

Hamed Esmaeil Lashgarian; Vahid Adamii; Vajihe Ghorbanzadeh; Leila Chodari; Fayze Kamali; Soheila Akbari; Hassan Dariushnejad

doi:10.1055/a-1223-1734

Drug Research, Table of Contents

Drug Res (Stuttg) 2020; 70(10): 478-483
DOI: 10.1055/a-1223-1734

Original Article

Silibinin Inhibit Cell Migration through Downregulation of RAC1 Gene Expression in Highly Metastatic Breast Cancer Cell Line

Hamed Esmaeil Lashgarian

¹Department of Medical Biotechnology, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran

,

Vahid Adamii

¹Department of Medical Biotechnology, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran

,

Vajihe Ghorbanzadeh

²Razi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran

,

Leila Chodari

³Department of Physiology, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran

⁴Neurophysiology Research Center, Urmia University of Medical Sciences, Urmia, Iran

,

Fayze Kamali

¹Department of Medical Biotechnology, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran

,

Soheila Akbari

⁵Department of Obstetrics and Gynecology, Lorestan University of Medical Sciences, Khorramabad, Iran

,

Hassan Dariushnejad

¹Department of Medical Biotechnology, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran

²Razi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran

› Author Affiliations

Abstract

Background Triple negative breast cancer is the most invasive breast cancer subtype and possesses poor prognosis and survival. Rho GTPase famil, especially Rac1 participates in a number of signaling events in cells with crucial roles in malignancy, migration and invasion of tumor cells. Silibinin, a flavonoid antioxidant from milk thistle has attracted attention in the recent decades for chemoprevention and chemotherapy of tumor cells. In this study, the effect of silibinin on the migration capacity of MDA-MB-231 cells, a highly metastatic human breast cancer cell line was investigated by evaluation of Rac1 expression.

Method MTT wound healing and transwell assays were performed to evaluate the effects of silibinin on proliferation and migration of MDA-MB-231 cells. In addition, the influence of the silibinin on the expression of Rac1mRNAs was assessed by RT-PCR.

Results Results indicated significant dose-dependent inhibitory effect of silibinin on proliferation and migration of MDA-MB-231 cells. It significantly inhibited the expression of Rac1 mRNA.

Conclusion In conclusion, the results demonstrate that the silibinin can be used as an experimental therapeutic for the management of TNBC metastatic cancer.

Key words

silibinin - breast cancer - TNBC - Rac1 - metastasis

Full Text

References

References
1 Di Micco R, Santurro L, Gasparri ML, Zuber V, Fiacco E, Gazzetta G, et al. Rare sites of breast cancer metastasis: a review. Translational Cancer Research. 2019
2 Razak NA, Abu N, Ho WY, Zamberi NR, Tan SW, Alitheen NB. et al. Cytotoxicity of eupatorin in MCF-7 and MDA-MB-231 human breast cancer cells via cell cycle arrest, anti-angiogenesis and induction of apoptosis. Scientific Reports 2019; 9
3 Kopfstein L, Christofori G. Metastasis: cell-autonomous mechanisms versus contributions by the tumor microenvironment. Cellular and Molecular Life Sciences CMLS 2006; 63: 449-468
4 Iden S, Collard JG. Crosstalk between small GTPases and polarity proteins in cell polarization. Nature Reviews Molecular Cell Biology 2008; 9: 846
5 Yang Z, Chen H, Shu M, Zhang Y, Xue L, Lin Y. DLC2 operates as a tumor suppressor gene in breast cancer via the RhoGTPase pathway. Oncology Letters 2019; 17: 2107-2116
6 Xiao Y, Li Y, Tao H, Humphries B, Li A, Jiang Y. et al. Integrin α5 down-regulation by miR-205 suppresses triple negative breast cancer stemness and metastasis by inhibiting the Src/Vav2/Rac1 pathway. Cancer Letters 2018; 433: 199-209
7 Karpel-Massler G, Westhoff M-A, Zhou S, Nonnenmacher L, Dwucet A, Kast RE. et al. Combined inhibition of HER1/EGFR and RAC1 results in a synergistic antiproliferative effect on established and primary cultured human glioblastoma cells. Molecular Cancer Therapeutics 2013; 12: 1783-1795
8 Bosco E, Mulloy J, Zheng Y. Rac1 GTPase: a “Rac” of all trades. Cellular and Molecular Life Sciences 2009; 66: 370
9 Kiosses WB, Shattil SJ, Pampori N, Schwartz MA. Rac recruits high-affinity integrin αvβ3 to lamellipodia in endothelial cell migration. Nature Cell Biology 2001; 3: 316
10 Yamazaki D, Kurisu S, Takenawa T. Regulation of cancer cell motility through actin reorganization. Cancer Science 2005; 96: 379-386
11 Abotaleb M, Samuel SM, Varghese E, Varghese S, Kubatka P, Liskova A. et al. Flavonoids in cancer and apoptosis. Cancers 2019; 11: 28
12 Abbaszadeh H, Keikhaei B, Mottaghi S A review of molecular mechanisms involved in anticancer and antiangiogenic effects of natural polyphenolic compounds. Phytotherapy Research 2019; 33: 2002-2014
13 Si L, Liu W, Hayashi T, Ji Y, Fu J, Nie Y. et al. Silibinin-induced apoptosis of breast cancer cells involves mitochondrial impairment. Archives of Biochemistry and Biophysics 2019; 671: 42-51
14 Yang Z, Pan Q, Zhang D, Chen J, Qiu Y, Chen X. et al. Silibinin restores the sensitivity of cisplatin and taxol in A2780-resistant cell and reduces drug-induced hepatotoxicity. Cancer Management and Research 2019; 11: 7111
15 Flaig TW, Gustafson DL, Su L-J, Zirrolli JA, Crighton F, Harrison GS. et al. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Investigational New Drugs 2007; 25: 139-146
16 Su Q, Peng M, Zhang Y, Xu W, Darko KO, Tao T. et al. Quercetin induces bladder cancer cells apoptosis by activation of AMPK signaling pathway. American Journal of Cancer Research 2016; 6: 498
17 Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007; 109: 1721-1728
18 Wu K-j ZengJ, Zhu G-d ZhangL-l, Zhang D, Li L. et al. Silibinin inhibits prostate cancer invasion, motility and migration by suppressing vimentin and MMP-2 expression. Acta Pharmacologica Sinica 2009; 30: 1162
19 Chang HR, Chen PN, Yang SF, Sun YS, Wu SW, Hung TW. et al. Silibinin inhibits the invasion and migration of renal carcinoma 786-O cells in vitro, inhibits the growth of xenografts in vivo and enhances chemosensitivity to 5-fluorouracil and paclitaxel. Molecular Carcinogenesis 2011; 50: 811-823
20 Nejati-Koshki K, Akbarzadeh A, Pourhasan-Moghaddam M, Abhari A, Dariushnejad H. Inhibition of leptin and leptin receptor gene expression by silibinin-curcumin combination. Asian Pacific Journal of Cancer Prevention 2013; 14: 6595-6599
21 Tiwari P, Mishra K. Silibinin in cancer therapy: A promising prospect. Cancer Res Front 2015; 1: 303-318
22 Deep G, Agarwal R. Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer and Metastasis Reviews 2010; 29: 447-463
23 Byun HJ, Darvin P, Kang DY, Sp N, Joung YH, Park JH. et al. Silibinin downregulates MMP2 expression via Jak2/STAT3 pathway and inhibits the migration and invasive potential in MDA-MB-231 cells. Oncology Reports 2017; 37: 3270-3278
24 Chen J, Thompson LU. Lignans and tamoxifen, alone or in combination, reduce human breast cancer cell adhesion, invasion and migration in vitro. Breast Cancer Research and Treatment 2003; 80: 163-170
25 De P, Aske JC, Dey N. RAC1 Takes the Lead in Solid Tumors. Cells 2019; 8: 382